Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Metastatic Sites of HER2-Overexpressing Primary Breast Tumors

2012 ◽  
Vol 2012 ◽  
pp. 75-76 ◽  
Author(s):  
J.T. Thigpen
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Breast Tumors ◽  
Her2 Expression ◽  
Human Epidermal Growth Factor ◽  
Epidermal Growth ◽  
Metastatic Sites

scholarly journals Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors

Cancer ◽  
2013 ◽  
Vol 119 (11) ◽  
pp. 1960-1968 ◽  
Author(s):  
David Groheux ◽  
Mathieu Hatt ◽  
Elif Hindié ◽  
Sylvie Giacchetti ◽  
Patricia de Cremoux ◽  
...  
Keyword(s):  
Estrogen Receptor ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Breast Tumors ◽  
Human Epidermal Growth Factor ◽  
Estrogen Receptor Positive ◽  
Epidermal Growth

scholarly journals Relations of Human Epidermal Growth Factor Receptor 2 (HER2) Expression and E-Cadherin (CDH1) Expression in Breast Cancer Patients

Biomedika ◽  
2021 ◽  
Vol 14 (1) ◽  
pp. 1-8
Author(s):  
Martga Bella Rahimi ◽  
Wirsma Arif Harahap ◽  
Yanwirasti Yanwirasti
Keyword(s):  
Breast Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Cancer Patients ◽  
Growth Factor Receptor ◽  
Her2 Expression ◽  
Breast Cancer Patients ◽  
Human Epidermal Growth Factor ◽  
Epidermal Growth

The aim of this study is to analyze the relations of Human Epidermal Growth Factor Receptor 2 (HER2) expression and E-Cadherin (CDH1) expression in breast cancer patients. To date, the synergistic effect of this CDH1/HER2 complex is not well clarified. The design of this study was cross-sectional with a total sample of 56 formalin-fixed paraffin tissue blocks that had been examined for HER2. Furthermore, CDHI expression was examined using the Immunohistochemistry staining technique with the Labeled Streptavidin Biotin Complex (LSAB) method. Bivariate analysis was performed using the Spearman correlation test with abnormally distributed data (p>0.05). Of the 56 data on breast cancer patients, most of the patients (87.5%) were diagnosed at the age of ≥40 years. The majority of cancer staging was IIIB, which was 42.9% of the total 56 patients. The study results shows that 80.0% of HER2-positive patients were in the strong CDH1 group. From these data, there is evidence of correlation between HER2 expression and CDH1 expression in breast cancer patients, however this correlation was not significant (p>0.05).

Sign in / Sign up

Export Citation Format

Share Document